Every month, around day 20 of her cycle, Sarah would describe it as "becoming someone else." Not mildly irritable. Not a bit weepy. A complete personality shift — sudden rage, paralysing anxiety, the conviction that her life was falling apart. Then, within hours of her period starting, it lifted. As though someone had flipped a switch.
Sarah does not have PMS. She has premenstrual dysphoric disorder (PMDD), and it took her six years and four doctors to get that diagnosis. Her story is not unusual. PMDD affects 5–10% of menstruating women — roughly 1 in 12 — yet the average diagnostic delay is 12 years, according to the International Association for Premenstrual Disorders (IAPMD).
PMS and PMDD are not the same condition
PMS is common. Up to 75% of menstruating women experience some premenstrual symptoms — bloating, breast tenderness, irritability, food cravings. These are inconvenient but manageable. They do not derail your life.
PMDD is a different beast entirely. It is classified in the DSM-5 as a depressive disorder, not a gynaecological condition. The hallmark is severe mood disturbance — depression, anxiety, anger, or emotional instability — that emerges in the luteal phase and resolves within days of menstruation.
Key differences
- PMS: Physical symptoms dominate (bloating, headaches, fatigue). Mood changes are mild.
- PMDD: Emotional symptoms dominate (rage, despair, anxiety, hopelessness). Physical symptoms may also be present but are secondary.
- PMS: Symptoms are annoying but do not impair daily functioning.
- PMDD: Symptoms cause significant impairment — relationship conflict, work absences, suicidal ideation in 30% of cases.
- PMS: Usually manageable with lifestyle adjustments.
- PMDD: Often requires medical treatment (SSRIs, hormonal interventions, or both).
The diagnostic criteria
PMDD requires at least five symptoms from the DSM-5 criteria, present in most menstrual cycles over the past year, with at least one being a core mood symptom. Crucially, symptoms must be confirmed by prospective daily tracking for at least two consecutive cycles — retrospective recall alone is not sufficient for diagnosis.
Core mood symptoms (at least one required)
- Marked affective lability — sudden sadness, tearfulness, or heightened sensitivity to rejection
- Marked irritability, anger, or increased interpersonal conflict
- Marked depressed mood, hopelessness, or self-deprecating thoughts
- Marked anxiety, tension, or feeling keyed up or on edge
Additional symptoms (enough to total five overall)
- Decreased interest in usual activities
- Difficulty concentrating
- Lethargy, fatigue, or marked lack of energy
- Marked change in appetite, overeating, or food cravings
- Hypersomnia or insomnia
- Feeling overwhelmed or out of control
- Physical symptoms: breast tenderness, bloating, joint pain, weight gain
Self-Assessment
Track your symptoms daily for two full cycles using a standardised tool like the Daily Record of Severity of Problems (DRSP). Rate mood, anxiety, irritability, and functioning each day on a 1–6 scale. If your scores are consistently low in the follicular phase and spike dramatically in the luteal phase, bring this data to your GP.
What causes PMDD
PMDD is not caused by abnormal hormone levels. Women with PMDD have the same oestrogen and progesterone levels as women without it. The difference is in the brain's response to those hormones.
Research from the National Institutes of Health (2017) demonstrated that women with PMDD have an altered response to allopregnanolone — a metabolite of progesterone that normally acts as a calming agent on GABA receptors. In most women, rising allopregnanolone in the luteal phase reduces anxiety. In women with PMDD, the same compound paradoxically increases it.
PMDD is an abnormal response to normal hormonal changes. The hormones are not the problem — the cellular sensitivity to them is.
— Dr Tory Eisenlohr-Moul, University of Illinois at Chicago
Genetic studies have identified a gene complex called ESC/E(Z) that governs cellular sensitivity to sex hormones. A 2017 study in Molecular Psychiatry found this gene complex is differentially expressed in women with PMDD, providing the first biological explanation for why some women are vulnerable and others are not.
What actually helps
SSRIs — the first-line treatment
Selective serotonin reuptake inhibitors are the most evidence-supported treatment for PMDD. Unlike their use in major depression (where they take 4–6 weeks to work), SSRIs for PMDD can take effect within days. This is because they work through a different mechanism in PMDD — increasing allopregnanolone synthesis rather than simply elevating serotonin.
Many women take SSRIs only during the luteal phase (roughly days 14–28) rather than continuously. A 2012 Cochrane review confirmed that luteal-phase-only dosing is as effective as continuous dosing for PMDD, with fewer side effects. Fluoxetine (10–20mg) and sertraline (50–100mg) have the strongest evidence base.
Lifestyle interventions
For mild-to-moderate symptoms, lifestyle changes can make a meaningful difference, though they are rarely sufficient for severe PMDD on their own.
- Calcium supplementation — 1200mg/day reduced PMS/PMDD symptoms by 48% in a randomised controlled trial (Thys-Jacobs et al., American Journal of Obstetrics and Gynecology, 1998)
- Aerobic exercise — 150 minutes/week of moderate cardio reduced luteal phase depression scores by 30% (University of Melbourne, 2019)
- Cognitive behavioural therapy (CBT) — specifically adapted for PMDD, targeting catastrophic thinking patterns that amplify luteal phase mood shifts
- Chasteberry (Vitex agnus-castus) — modest evidence from a 2017 meta-analysis in the Journal of Psychosomatic Obstetrics & Gynecology. Effect size smaller than SSRIs but meaningful for some women.
- Reducing alcohol and caffeine in the luteal phase — both can worsen anxiety and sleep disruption
Hormonal approaches
Some women benefit from suppressing ovulation entirely. Continuous combined oral contraceptives (no pill-free break) or GnRH agonists eliminate the hormonal fluctuations that trigger PMDD. These are typically second-line options when SSRIs are insufficient or not tolerated.
The importance of naming it
For many women, the diagnosis itself is transformative. Years of being told they are "too sensitive," "hormonal," or "dramatic" finally have context. PMDD is a neurobiological condition with a genetic basis. It is not a character flaw.
If you recognise yourself in this article, start tracking. Two months of daily symptom data is the single most powerful diagnostic tool you have. It turns a subjective complaint into objective evidence — evidence that clinicians cannot easily dismiss.
Urgent Support
If you experience suicidal thoughts during the luteal phase, this is a recognised feature of severe PMDD. Contact the Samaritans (116 123), SHOUT (text 85258), or your GP urgently. You are not overreacting. This is a treatable medical condition.